Immunology

Showing 15 posts of 75 posts found.

Mavatar announces research collaboration with Sobi

January 6, 2026
Research and Development Immunology, Mavatar, Rare Diseases, sobi

Mavatar has announced the initiation of a non-clinical research collaboration with Sobi, using Mavatarโ€™s technology to generate data insights into …

STADA and Bio-Theraโ€™s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025
Research and Development Bio-Thera, Immunology, Stada

STADA and Bio-Theraโ€™s Gotenfia (golimumab), a biosimilar of Janssenโ€™s Simponi, has received a positive opinion from the European Medicines Agency …

Celltrionโ€™s Remsima IV approved by EC in liquid form

November 27, 2025
Research and Development Celltrion Inc, Immunology

Celltrionโ€™s Remsima IV, the first-ever liquid formulation of infliximab for autoimmune diseases, has been approved by the European Commission (EC). …

Alvotech biosimilar receives EC marketing approval

November 26, 2025
Research and Development Alvotech, Immunology, Inflammatory disease, Rheumatology

The European Commission (EC) has granted marketing authorisation for Gobivaz, Alvotechโ€™s first-in-market biosimilar of Simponi (golimumab), which is used for …

Neogap Therapeutics appoints Jonas Mattson to its board of directors

August 26, 2025
Research and Development Corporate, Immunology, Neogap Therapeutics, Oncology, board of directors

Swedish biotech, Neogap Therapeutics, has appointed Jonas Mattson, an authority in cell therapy, to its board of directors. His appointment …

Astra Zeneca Logo

NICE recommends Benralizumab for Rare Form of Vasculitis

August 15, 2025
Medical Communications, Research and Development AstraZeneca, Immunology, National Institute for Health and Care Excellence, vasculitis

The National Institute for Health and Care Excellence (NICE) has recommended AstraZenecaโ€™s benralizumab (Fasenra) as an add-on treatment for adult …

drug-trials

Novartis candidate for Sjรถgrenโ€™s disease presents positive results

August 15, 2025
Research and Development Immunology, Novartis, Sjรถgrenโ€™s disease, US Food and Drug Administration, clinical trial

Novartis has reported positive results from two phase 3 clinical trials โ€“ NEPTUNUS-1 and NEPTUNUS-2 โ€“ evaluating ianalumab in adults …

CuraCell granted approval for trial of new therapy for metastatic cancers

August 13, 2025
Research and Development CuraCell, Immunology, clinical trial, immunotherapy, metastic cancer

Swedish immunotherapy company, CuraCell, has received approval from the Paul-Ehrlich-Institut in Germany to begin a phase 1/2a clinical trial of …

A challenge we can no longer ignore: meeting the needs of people with Crohnโ€™s Disease in the UK

August 3, 2025
Research and Development Crohnโ€™s disease, Immunology, Lilly UK, autoimmune disease, immunology

By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in the UK is at a …

Amarna Therapeutics and NorthX Biologics collaborate to advance gene therapy for type 1 diabetes

July 10, 2025
Mergers and Acquisitions, Research and Development Amarna Therapeutics, Diabetes, Immunology, NorthX Biologics, Type 1 diabetes, gene therapy, immune-mediated diseases

Amarna Therapeutics and NorthX Biologics have finalised an agreement to accelerate the development of Nimvec AM510, a gene therapy targeting …

Richard Philipson appointed as chief medical officer of Hansa Biopharma

July 9, 2025
Research and Development Hansa Biopharma, Immunology, chief medical officer, immunology

Hansa Biopharma has announced that Richard Philipson has been appointed chief medical officer, effective 14 July. Philipson will join the …

hospital_ward

FDA approves Gamifant for macrophage activation syndrome in Stillโ€™s disease

June 30, 2025
Medical Communications, Research and Development FDA, Immunology, Still's disease, gamifant, hemophagocytic lymphohistiocytosis, sobi

The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in …

Photo of patient

FDA grants orphan drug designation to antibody-mediated rejection treatment

June 26, 2025
Research and Development FDA, Immunology, Orphan Drug Designation, Sanofi, antibody-mediated rejection, clinical trials, immunology, inflammation, organ transplantation

Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for …

The Gateway to Local Adoption Series

Latest content